Objectives: Over 2 million individuals are infected with HIV type 1 (HIV-1) each year, yet an effective vaccine remains elusive. The most successful HIV-1 vaccine to date demonstrated 31% efficacy. Immune correlate analyses associated HIV-1 envelope (Env)-specific antibodies with protection, thus providing a path toward a more effective vaccine. We sought to test the antibody response from novel prime-boost vaccination with a chimpanzee-derived adenovirus (AdC) vector expressing a subtype C Env glycoprotein (gp)140 combined with either a serologically distinct AdC vector expressing gp140 of a different subtype C isolate or an alum-adjuvanted, partially trimeric gp145 from yet another subtype C isolate.
Introduction
In total, 35 million people are living with HIV and over 2 million become infected each year. Despite advances in therapy, HIV causes over 1.5 million deaths annually. A vaccine to prevent HIV type 1 (HIV-1) infection could drastically reduce the global burden of disease. A desirable immune target is the trimeric HIV envelope (Env) glycoprotein (gp) that facilitates entry into susceptible host cells, which can be blocked by antibodies.
The complexity of the virus presents challenges for an efficacious vaccine. There have been six HIV-1 vaccine efficacy trials to date [1] [2] [3] [4] [5] . The RV144 trial, which tested priming with a canarypox vector expressing Gag, Pol, and Env, and boosting with monomeric gp120 protein, resulted in 31.2% efficacy [6] . This offered the first indication that a vaccine could prevent HIV-1 infection, albeit with modest and transient efficacy. IgG antibodies, specifically IgG3 targeting the variable region 2 (V2) of gp120, correlated with decreased risk of infection [7] [8] [9] .
Adenovirus vectors of human serotype 5 are potent inducers of T and B-cell responses, but failed in HIV-1 vaccine trials, in part because of preexisting immunity to the vaccine vector [10] . Vaccines based on alternative adenoviruses, with lower seroprevalence in humans such as those derived from chimpanzees (AdC), might be more advantageous [11] . Several AdC vectors have been shown to be highly immunogenic in mice and nonhuman primates [12, 13] . In addition, prime-boost regimens based on AdC7 and AdC6 demonstrate induction of potent and sustained transgene-specific T and B-cell responses [14] .
Trimeric HIV-1 Env may elicit improved immune responses compared with monomeric gp120, as it may be more representative of a functional Env trimer on the surface of the virion [15] . Several trimeric Env proteins have recently been shown to elicit neutralizing antibodies (NAbs) in preclinical studies [16] [17] [18] . The CO6980 gp145 Env, isolated from an acute, subtype C infection, represents a tier 2 HIV-1 Env with an intact membraneproximal external region extended by three Lys residues that binds to integrin a4b7 and several mAbs, including V2 mAbs. Immunization of rabbits elicited binding antibodies to Env, including V1V2 and V3 specificities, and cross-reactive NAbs [16] .
We tested AdC vectors and recombinant protein in prime-boost vaccine strategies, utilizing replicationdefective AdC vectors expressing subtype C Env without the transmembrane domain (gp140), and subtype C gp145 protein, CO6980 [16] . We assessed the immunogenicity of six prime-boost regimens, categorized as three prime-boost strategies tested at two AdC vector doses. The first strategy involved priming three times with gp145 protein followed by boosting with AdC vector, the second primed once with AdC vector then boosted three times with gp145. The third primed once with AdC vector then boosted once with a heterologous AdC vector.
Boosting AdC vector-primed mice with the heterologous AdC vector or alum-adjuvanted gp145 protein significantly enhanced Env-specific antibody responses, including V2-specific binding antibodies. Priming with protein followed by AdC vector boost was relatively ineffective. Induction of NAbs that cross-reacted between different clades required inclusion of protein into the vaccine regimen. This study warrants further investigation of AdC vector and gp145 protein primeboost vaccines.
Methods

Vaccines
Adenovirus vectors based on chimpanzee serotypes SAd-V24 (AdC7) and SAd-V23 (AdC6) were early region (E)1 deleted, generated from recombinant viral molecular clones, and encode HIV-1 subtype C gp140 transgenes, strain Du172 and Du422, respectively. Vectors were produced, purified, titrated, and quality controlled as described [13] .
Construction and production of gp145 CO6980 Env protein subtype C have been described [16] . Briefly, CO6980 Env was expressed in Chinese hamster ovary clone K1 cells and purified by lectin affinity chromatography with Galanthus nivalis lectin agarose (Vector Laboratories, Burlingame, California, USA) followed by anion exchange on Q Sepharose fast flow (GE Healthcare, Little Chalfont, UK). Protein was further concentrated, exchanged into phosphate-buffered saline (PBS), and sterile filtered. Oligomeric form was determined to be about 60% trimeric by negative stain electron microscopy.
Vaccination protocol
Female outbred Crl:CD1 (ICR) mice were treated at the Wistar Institute Animal Facility following approved procedures. Vaccines were administered intramuscularly at 200 ml/dose. AdC gp140 vectors were given in PBS; gp145 protein was given at 10 mg/dose in a 1% aluminum hydroxide gel suspension (alum) (Sigma-Aldrich, St. Louis, Missouri, USA).
Serum isolation
Serum prepared from whole blood was frozen at À208C.
IgG ELISA Sera were tested for HIV-1 gp140-specific and V2-specific antibodies by ELISA on plates coated with gp140 protein or linear V2 peptide, respectively. HIV-1 strain Du172 gp140 protein was produced in baculovirus [19] . V2 peptide was based on a 19-amino-acid immunodominant linear epitope within V2 of HIV-1 strain Du172: TTTEITDKKKKEYALFYKL (Genscript, Piscataway, New Jersey, USA) [20] . gp140-specific IgG was tested in two-fold serum dilutions from 1 : 1000-1 : 16 000. V2-specific IgG was tested using two-fold serum dilutions from 1 : 100-1 : 6400. Briefly, 96-well plates (Nunc-Immuno Microwell, Sigma-Aldrich) were coated overnight at 48C with gp140 protein (200 ng/well) or V2 peptide (400 ng/well). Wells were blocked overnight at 48C with PBS/3% bovine serun albumin (BSA)/0.1% Tween-20 or PBS/8% BSA/0.1% Tween-20. Duplicate samples and a standard were incubated at room temperature (RT) for 2 h or 90 min. Bound IgG was detected with goat antimouse IgG alkaline phosphatase conjugate (Sigma-Aldrich) at 1 : 30 000 or 1 : 15 000. Bound enzyme was detected with phosphatase substrate tablets (Sigma-Aldrich) in diethanolamine (DEA) substrate buffer (Kirkegaard & Perry Lab Inc., Gaithersburg, Maryland, USA) by optical density (OD) at 405 nm. Gp140-specific IgG is reported as area under the curve for 1 : 2000-1 : 16 000 dilution curves. V2-specific IgG is reported as OD at 1 : 100 dilution.
Subisotype ELISA
Subisotyping was performed similarly as above except bound antibody was detected using rabbit antimouse IgG1, IgG2a, IgG2b, IgG3, IgA, and IgM (Calbiochem, San Diego, California, USA) and goat antirabbit IgG alkaline phosphatase conjugate (Sigma-Aldrich). gp140specific and V2-specific subisotypes were tested at serum dilutions of 1 : 2000 and 1 : 200, respectively.
Avidity ELISA Avidity of gp140-specific antibodies was assessed by sodium thiocyanate (NaSCN)-displacement ELISA. Briefly, samples were diluted to 1 : 2000 in PBS/3% BSA/0.1% Tween-20 and incubated for 2 h at RT on 96-well plates (Nunc-Immuno Microwell) coated with HIV-1 gp140 strain Du172. Ascending concentrations of the chaotropic agent NaSCN were added to the wells (0-4 mol/l). Plates were incubated for 15 min at RT, then treated with goat antimouse IgG alkaline phosphatase conjugate (Sigma-Aldrich) at 1 : 30 000. Bound enzyme was detected as above by OD at 405 nm.
Pseudovirus preparation
Pseudovirus was prepared as previously described [21] . The following pseudoviruses were produced: GS015 and MW965, both tier 1 subtype C; TH023, tier 1 CRF01_AE; SF162, tier 1 subtype B; TZBD 9/11, tier 2 subtype C; and murine leukemia virus (MuLV) (nonspecific control).
High-throughput pseudovirus neutralization assay
NAb titers were determined using TZM-bl cells in a high-throughput assay utilizing robotic liquid handling. Serum was diluted 1 : 10 in growth medium and serially diluted using the Biomek NXP liquid handler (Beckman Coulter, Indianapolis, Indiana, USA) [22] . Titered serum (12.5 ml/well) was transferred to 384-well culture plates and incubated with an equal volume of pseudovirus for 45 min at 378C. TZM-bl cells (3 Â 10 3 cell/well) with diethylaminoethyl (DEAE)-dextran (25 mg/ml) were added to each well and incubated for an additional 48 h. Relative light units were detected with the SpectraMax Paradigm Microplate Reader (Molecular Devices, Sunnyvale, California, USA) using the Bright-Glo Luciferase Assay System (Promega Corporation, Madison, Wisconsin, USA). Percentage neutralization (percentage reduction of relative light units in the presence of serum) was calculated for each serum dilution. Neutralization dose-response curves were fitted by nonlinear regression using the LabKey Server (Seattle, Washington, USA), and the final titer is reported as the reciprocal of the dilution of serum necessary to achieve 50% neutralization (50% inhibitory dose).
Statistical analysis
One-way ANOVA was used with Holm-Sidak correction for comparing three or more parameters for one group or one parameter for three or more groups. Twoway ANOVA was used with Holm-Sidak correction for comparing multiple parameters among three or more groups. Analyses were performed in GraphPad Prism 6 (La Jolla, California, USA). In Figs 2-5, multiplicity adjusted P values are reported within the graphs using the following symbols: -for P greater than or equal to 0.05, Ã for P between 0.01 and 0.05, ÃÃ for P between 0.001 and 0.01, ÃÃÃ for P between 0.0001 and 0.001, and ÃÃÃÃ for P less than 0.0001.
Results
Study design and vaccines
The study design is shown in Fig. 1a . Groups 1 and 2 tested protein prime at day 0, week 4, and week 8 followed by a boost with 10 10 or 10 9 virus particles (vp) of AdC7 at week 12. Groups 3 and 4 tested AdC prime at the two doses followed by protein boosts at weeks 8, 12, and 18. Groups 5 and 6 tested priming with 10 10 or 10 9 vp of AdC7 at day 0 and boosting with heterologous AdC6 using the same doses at week 8. Sera were collected at the indicated time points.
Magnitude and kinetics of antibody responses
Adenovirus vectors are very immunogenic and induce both B cell and T-cell responses [10, 13, 14] . These responses can be boosted by heterologous vaccines, such as a protein or an adenovirus vector from a different serotype. We sought to determine which of the six immunization regimens elicited the highest and most sustained HIV-1 Env-specific antibody response. In addition, the study was designed to assess if any of the regimens allowed for dose sparing of the AdC vector.
Binding antibody responses to gp140 Env strain Du172 subtype C are shown for individual mice (Fig. 1b and c) and for mean response by group ( Fig. 1d and e ). We sought to determine whether the prime-boost regimen increased antibody titers over baseline response (week 0), whether boosting increased antibody titers over that induced by the prime, and whether antibody titers were sustained. For this analysis, antibody titers were compared within each group at all the time points (weeks 0 through 24). In the AdC7/protein 10 10 group, there was a significant increase in antibody titers from baseline beginning at week 4 and all the time points thereafter (P values reported in the figure legend and Supplement Table 1 , http://links.lww.com/QAD/A968). In the AdC7/protein 10 9 group, a significant increase in titers from baseline was first seen after the protein boost (week 12) and was maintained thereafter. For both doses of AdC7/protein, there was a significant increase from responses 4 and 8 weeks after AdC7 prime and all time points after the protein boosts. However, for both AdC7/ protein groups, there were no significant differences among antibody responses at weeks 12, 18, 20, and 24, indicating that the second and third protein boosts did not increase titers. For both doses of AdC7/AdC6, a significant increase in titers from baseline was first seen after the AdC6 boost. There was a significant increase from the response 4 weeks after AdC7 prime to all time points following the AdC6 boost. In addition, the 10 9 vp 2408 AIDS 2016, Vol 30 No 16 ). All statistical comparisons were made by two-way ANOVA and Holm-Sidak multiple comparisons test. The following significant multiplicity adjusted P values were obtained: comparing response over time within each group: (d) AdC7/protein 10 10 : week 0 vs. weeks 4-24 P < 0.0001 to P ¼ 0.0009, week 4 vs. weeks 12-24 P < 0.0001, week 8 vs. weeks 12-24 P < 0.0001 to P ¼ 0.0014; AdC7/AdC6 10 10 : week 0 vs. weeks 12-24 P < 0.0001, week 4 vs. weeks 12-24 P ¼ 0.0034 to 0.0088; protein/AdC7 10 10 : week 0 vs. weeks 18-24 P ¼ 0.0018 to 0.0044, week 4 vs. weeks 18-24 P ¼ 0.0079 to 0.0174; (e) AdC7/protein 10 9 : week 0 vs. weeks 12-24 P < 0.0001, week 4 vs. weeks 12-24 P < 0.0001, week 8 vs. weeks 12-24 P < 0.0001; AdC7/AdC6 10 9 : week 0 vs. weeks 12-24 P < 0.0001 to P ¼ 0.0003, week 4 vs. weeks 18-24 P ¼ 0.0005 to 0.0078, week 8 vs. week 24 P ¼ 0.0381. Comparing different regimens at same dose: (d) AdC7/protein 10 10 greater than protein/AdC710 10 : weeks 8-24 P < 0.0001 to P ¼ 0.0204; AdC7/protein 10 10 greater than AdC7/AdC6 10 10 : week 8 P ¼ 0.0451, weeks 12-24 P < 0.0001 to P ¼ 0.0025; (e) AdC7/protein 10 9 greater than protein/AdC7 10 9 : weeks 12-24 P ¼ 0.0003 to 0.0034; AdC7/AdC6 10 9 greater than protein/AdC7 10 9 : week 24 P ¼ 0.0436. Comparing AdC dose for same regimen: AdC7/protein 10 10 greater than AdC7/protein 10 9 : week 8 P ¼ 0.0191. AdC7/AdC6 group showed a difference between week 8 after AdC7 prime, the time point immediately prior to AdC6 boost, and week 24. In the protein/AdC7 10 10 group, a significant increase in titers from baseline was seen after the AdC7 boost. An increase in titers from week 4 was seen following the AdC7 boost. There were no significant differences in antibody titers over baseline or among time points in the protein/AdC7 10 9 group.
We sought to determine if one type of prime-boost regimen offered an advantage over the others. We compared the different regimen types at each dose of AdC. When comparing the three regimens at the 10 10 vp dose of AdC (Fig. 1d) , the AdC7/protein regimen elicited the highest titers of binding antibodies. Antibody responses to the AdC7/protein regimen were significantly greater than those to the protein/AdC7 regimen by 8 weeks after priming (P ¼ 0.0204) and significant differences were maintained through week 24. AdC7/ protein induced higher responses than AdC7/AdC6 by 4 weeks after the first boost, which were sustained through week 24. There was a marginally higher response in AdC7/protein compared with AdC7/AdC6 at week 8 (P ¼ 0.0451) despite receiving the same prime, however, after boosting the difference was highly significant (week 12; P < 0.0001). There were no significant differences between the protein/AdC7 and AdC7/AdC6 regimens. When comparing the three regimens at the 10 9 vp dose of AdC (Fig. 1e) , the AdC7/protein-induced antibody response was significantly greater than that elicited by protein/AdC7 from weeks 12 through 24. The AdC7/AdC6 response was greater than the protein/ AdC7 response only at week 24. There were no significant differences in responses when comparing the AdC7/protein and AdC7/AdC6 regimens at the 10 9 vp dose.
We were interested in ascertaining whether dose sparing of the AdC vector is possible. Thus, we compared the two doses (10 10 and 10 9 vp AdC) for each regimen type. In the AdC7/protein regimens, antibody response were significantly higher in the 10 10 vp group as compared with the 10 9 vp group at 8 weeks postprime (P ¼ 0.0191), differences observed at other time points were not significant. For both the protein/AdC7 regimens and the AdC7/AdC6 regimens, there were no differences between the 10 10 and 10 9 vp groups.
As we showed previously, antibody responses induced by adenovirus vectors are extremely stable, which may reflect the low-level in-vivo persistence of adenovirus vectors [23, 24] . We tested some of our mice 46 weeks after priming and their titers were comparable with those tested earlier at week 18. Using a different monomeric gp140 for a single boost of an AdC-induced antibody response showed that responses, once they peaked around week 18, remained stable through week 46 (data not shown).
Overall, these results show that boosting of an AdC vector with a serologically distinct AdC vector or an alumadjuvanted gp145 protein significantly enhances antibody responses. Interestingly, repeated immunizations with the gp145 protein did not significantly increase antibody responses nor did it seem to affect response longevity.
We further characterized the antibody response by isotype for all regimens ( Fig. 2a and b) . For groups primed with the AdC vector, the antibody response was primarily composed of IgG2a (55-65%) and IgG2b (25-36%) isotypes, indicative of responses driven by Th1 cells. We Fig. 2 . Antibody responses are primarily IgG2. AdC, chimpanzee-derived adenovirus; OD, optical density. Isotyping was performed by ELISA following the last immunization: protein/AdC7 groups at week 18, AdC7/protein groups at week 20, and AdC7/AdC6 groups at week 12. (a) At both AdC doses, AdC7/protein elicits a greater combined isotype response than protein/AdC7 and AdC7/AdC6 as indicated by Ã (10 10 dose P ¼ 0.0013, P ¼ 0.0034, respectively; 10 9 dose P ¼ 0.0085, P ¼ 0.0442, respectively). (b) Relative isotype frequency. Protein/AdC7 elicits IgG1 at a significantly greater frequency than both AdC7/protein and AdC7/AdC6, P < 0.0001. The AdC7-primed regimens, AdC7/protein, and AdC7/AdC6 predominantly elicit IgG2a and at greater frequency than protein/AdC7, P < 0.0001. The symbols Ã / Ã over part (b) represent the significance differences between groups for the isotypes IgG1 and IgG2a, respectively (two-way ANOVA with Holm-Sidak multiple comparisons test). also detected IgG1 (3-11%) in these groups, an isotype that is promoted by Th2 cells, but little to no IgG3, IgM, or IgA. In mice that were primed with protein, approximately half of the antibody response was comprised of IgG1 (44%), whereas IgG2a and IgG2b responses were comparable (22-30%) and we detected some IgG3, IgM, and IgA (0.5-3%). Comparing the groups within a given AdC vector dose showed significant differences in IgG1 and IgG2a between protein/AdC7 compared with AdC7/protein or AdC7/AdC6 (P < 0.0001). These data show that priming with the AdC vectors induced predominantly a Th1 response and that this was not modified by boosting with alum-adjuvated protein, which generally induces a Th2 response [25, 26] . Priming with protein, on the other hand, favored induction of a Th2 response.
Antibody function
We tested the avidity of the Env-specific antibodies induced by the vaccine regimens at the week following the last immunization (Fig. 3a) . The groups that received the protein immunizations first showed markedly lower avidity compared with the others and only retained 50% antibody binding at NaSCN concentrations slightly above 1 mol/l. The other groups retained 50% antibody binding at 2 mol/l NaSCN or greater (Fig. 3a) . To determine the effect of additional protein boosts on antibody avidity in the AdC7/protein 10 10 and AdC7/ protein 10 9 groups, samples from week 12, 18, and 20 were evaluated (Fig. 3b ). There were no significant differences in the avidity after additional protein boosts.
To assess a virus inhibitory function of the antibodies, we performed TZM-bl neutralization assays against four tier 1 pseudoviruses, MW965 (subtype C), GS015 (subtype C), SF162 (subtype B), and TH023 (subtype CRF01_AE), and one tier 2 pseudovirus, TZBD 9/11 (subtype C) ( Fig. 4) . A pseudovirus containing the Env from MuLV was tested as a nonspecific control. Sera were tested at different times after vaccination and the 50% inhibitory dose values were determined. Sera failed to neutralize MuLV (not shown). All of the vaccine regimes induced NAbs to MW965 pseudovirus, with the highest titers observed in the group receiving AdC7/protein 10 10 . Response rates to this virus, shown as the ratio of seropositive mice over all mice in a given group (Suppl. Fig 1, http://links.lww.com/QAD/A968), were comparable between all six groups (0.8) by the end of the study. Regimens that included immunizations with protein also induced cross-clade NAbs to other tier 1 viruses, although response rates were lower. Responses to the two AdC vectors were less broad. None of the regimens induced NAbs to the tier 2 subtype C virus.
V2-specific antibody response
We tested whether linear V2-specific antibodies, shown to be protective in the RV144 trial, were elicited by our vaccine regimens (Fig. 5a) [7] . Anti-V2 antibodies were detected in all vaccine groups. In the AdC7/protein 10 10 and AdC6/AdC7 10 10 groups, there were significant increases in V2-specific antibody titers from baseline (P < 0.0001 and P ¼ 0.0255, respectively). We characterized the V2-specific response by isotyping (Fig. 5b) . The NaSCN (mol/l) at 50% binding AdC7/protein 10 10 AdC7/protein 10 9
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Week 18 Week 12 Fig. 3 . Avidity of Env-specific antibody binding. AdC, chimpanzee-derived adenovirus. NaSCN-displacement ELISA performed. (a) Following last immunization: protein/AdC7 groups at week 18, AdC7/protein groups at week 20, and AdC7/AdC6 groups at week 12 and (b) on week 12, 18, 20 for AdC7/protein 10 10 and AdC7/protein 10 9 to determine effect of additional protein boosts on avidity. Results are reported as the concentration of NaSCN (mean AE SEM) at which IgG binding was reduced by 50% as compared with binding in the absence of NaSCN. (a) Avidity of AdC7/protein 10 10 is significantly greater than both protein/AdC7 10 10 and AdC7/AdC6 10 10 , P ¼ 0.0009 and P ¼ 0.0439, respectively, whereas AdC7/AdC6 10 10 is greater than protein/AdC7 10 10 , P ¼ 0.0339. At the 10 9 dose, AdC7/protein and AdC7/AdC6 avidities are significantly greater than that of protein/AdC7, P ¼ 0.0030 and P ¼ 0.0164, respectively. (b) No significant change in avidity is seen in the AdC7/protein groups with administration of additional protein boosts. (one-way ANOVA with Holm-Sidak multiple comparisons test).
AdC7/protein V2 response was dominated by IgG2a antibodies, whereas the other groups showed a more even distribution of IgG1, IgG2a, and IgM. IgM was overall higher than in the response to whole protein (Fig. 1) suggesting that the response to the V2 loop matures with a delay.
Discussion
AdC vaccines are being developed against several infectious diseases, including HIV-1, because of their low seroprevalence in humans compared with human adenovirus, their high immunogenicity, and ease of modification [23] [24] [25] . The HIV-1 CO6980 trimerenriched gp145 Env immunogen elicits advantageous antibody responses in rabbits and is undergoing GMP production for use in human clinical trials [16] . In this study, immunogenicity of novel vaccine regimens involving AdC vectors expressing a subtype C gp140 and heterologous CO6980 gp145 protein were tested in mice. The goal was to assess antibody responses elicited by three different prime-boost regimens (protein/AdC7, AdC7/protein, and AdC7/AdC6) at two different doses of AdC vector. . The following differences reached significance: MW965 PV: at week 18 AdC7/protein 10 10 greater than protein/AdC7 10 10 P ¼ 0.0258, AdC7/protein 10 10 greater than AdC7/AdC6 10 10 P ¼ 0.0317; GS015 PV: protein/ AdC7 10 10 greater than AdC7/protein 10 10 at week 20 P ¼ 0.0340, protein/AdC7 10 10 greater than AdC7/AdC6 10 10 at week 20 P ¼ 0.0102 and week 24 P ¼ 0.0424, AdC7/protein 10 9 greater than protein/AdC7 10 9 at week 24 P ¼ 0.0032, AdC7/protein 10 9 greater than AdC7/AdC6 10 9 at week 24 P ¼ 0.0057; TH023 PV: at week 12 AdC7/AdC6 10 9 greater than protein/AdC7 10 9 P ¼ 0.0073, AdC7/AdC6 10 9 greater than AdC7/protein 10 9 P ¼ 0.0115; SF162 PV: protein/AdC7 10 10 greater than AdC7/AdC6 10 10 at week 20 P ¼ 0.0318, protein/AdC7 10 9 greater than AdC7/protein 10 9 at week 12 P ¼ 0.0397, protein/AdC7 10 9 greater than AdC7/AdC6 10 9 at week 12 P ¼ 0.0397; TZBD PV: at week 20 AdC7/protein 10 9 greater than protein/AdC7 10 9 P ¼ 0.0055, AdC7/protein 10 9 greater than AdC7/AdC6 10 9 P ¼ 0.0055.
AdC7/protein regimen elicits significantly higher IgG titers compared with the protein/AdC7 and AdC7/ AdC6 regimens at certain doses. These results are consistent with other studies that demonstrate optimal immune responses from heterologous prime-boost vaccination, when protein is used as the boost [26] [27] [28] . The mechanism for higher antibody responses upon protein boost is not fully understood. We would assume it reflects that AdC vectors are by far more immunogenic than protein vaccines and are thereby better suited to drive activation of naive B cells, which can then be expanded by a less potent vaccine. However, further protein boosting did not significantly increase antibody titers. It was also not essential to ensure durability of the response as we tested for using a different gp140 protein for boosting (unpublished data). This suggests that heterologous protein boosts may be required or that a single-protein boost may suffice after an AdC vector prime. The latter would be highly advantageous considering the cost of protein vaccines and the complexity of multiple-dose regimens.
All of the vaccine regimens induced Env-specific IgG2b, which is the mouse isotype most closely related to IgG3 that was shown to be correlated with vaccine-induced resistance to HIV-1 infection in the RV144 trial [29] . Our results differ from the IgG1-biased response in a protein and DNA immunizations protocol [30] .
Antibody avidity was evaluated to determine the strength of antibody binding as an assessment of affinity maturation. Previous studies showed an inverse correlation between postchallenge viral titers and the avidity of antibodies induced by preventive vaccination [31] . Our study did not find significant differences in antibody avidity among the AdC7/protein and AdC7/AdC6 regimens but markedly lower avidity in mice that received the protein primes followed by an AdC7 boost.
Induction of potent, broadly cross-reactive NAbs is fervently pursued by HIV-1 vaccine researchers. They face many challenges, including extraordinary diversity of circulating strains, a high degree of glycosylation, and new epitopes revealed upon receptor and coreceptor binding. Large-scale clinical vaccine trials have induced low-titer NAbs with limited cross-reactivity [1, 2, 6] . Our vaccine regimens that included protein immunizations induced antibodies that were able to neutralize tier 1 viruses from subtype B, C, and CRF01_AE, although they failed to neutralize the one tier 2 virus tested. NAb responses to the AdC7/AdC6 immunization were less broad, which may reflect that the structure of viral transgene products is distinct from that of a trimeric protein immunogen. Notwithstanding, including an AdC vector into a vaccine regimen has the added advantage that all adenovirus vectors induce potent cellular immune responses (most notable CD8 þ T cells) to the transgene product, which may not prevent infection but allow for rapid viral clearance [32, 33] .
Other preclinical vaccine studies have also elicited NAbs; tier 1 and tier 2 pseudovirus neutralization was achieved with a DNA vaccine expressing gp160 given together with particles displaying the membrane-proximal Using preimmunization values as baseline, both the AdC7/protein 10 10 (P < 0.0001) and AdC7/AdC6 10 10 (P ¼ 0.0255) regimens elicited significant titers of V2-specific antibodies (two-way ANOVA and Holm-Sidak multiple comparisons test). (b) Relative percentages of V2 Du172-specific antibodies of the different isotypes at the week following last immunization using a serum dilution of 1 : 200. The symbols Ã / Ã over part b represent the significant differences between groups for the isotypes IgG2a and IgM, respectively (two-way ANOVA with Holm-Sidak multiple comparisons test). AdC7/ protein 10 9 elicits a greater frequency of IgG2a antibodies than protein/AdC7 10 9 , P < 0.0001. At both 10 10 and 10 9 , the percentage of IgG2a antibodies elicited by AdC7/protein is greater than AdC7/AdC6, P ¼ 0.0204 and P ¼ 0.0062, respectively. IgM antibodies are elicited at a greater frequency by protein/AdC7 10 9 as compared with AdC7/protein 10 9 , P ¼ 0.0345.
external region of Env [34] . Similar results were obtained with an adjuvanted DNA vaccine followed by a protein boost, as well as with a DNA prime/protein boost regimen using constructs that expressed diverse polyvalent heterotrimeric Envs [35, 36] . Careful design of immunogens and adjuvants thus allows for the induction of cross-reactive NAbs to HIV-1, which upon passive transfer have been shown to protect nonhuman primates against challenge with an HIV-1/simian immunodeficiency virus chimera and to reduce viral loads in chronically infected individuals in human trials [29, 30, 37] .
In the RV144 trial, protection was correlated with antibodies to the V2 of gp120 [7] . Subsequent studies confirmed these results in a nonhuman primate low-dose simian immunodeficiency virus challenge study [32] . The AdC7 vector followed by AdC6 or protein boost also induced V2-specific antibodies. This is in contrast to studies based on immunization with a monomeric gp120 protein [33] .
Altogether, our results are very promising as they show that a simple vaccine regimen can elicit cross-neutralizing (albeit tier 1 responses), as well as V2-specific antibodies in animals. Further studies are warranted in nonhuman primates to elucidate appropriate dosing of both the AdC7 vector and gp145 protein and to assess if antibodies provide protection against viral challenge.
